February 17th, 2012

Our Statement on Infants’ TYLENOL® Recall

From Jay Kosminsky, Vice President, Worldwide Communication and Public Affairs, Johnson & Johnson Consumer Companies, Inc.

This morning, after announcing a recall of an Infants’ TYLENOL® product, Denice Torres, who’s the President of McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, sent the following letter to Johnson & Johnson employees. I think it shows the passion of Denice and her team to bring McNeil back, and I’d like to share it with all of you. We’ve also reached out to consumers about the recall, including a video to help them understand the issue. I hope you’ll visit www.tylenol.com to learn more. Here’s Denice’s letter…

Dear Johnson & Johnson colleagues,

Today McNeil Consumer Healthcare announced a voluntary recall of the U.S., Infants’ TYLENOL® Oral Suspension, 1 oz. Grape. We’re recalling the product at the retail level after receiving a small number of complaints from consumers who reported difficulty using the product’s SimpleMeasure™ dosing system. SimpleMeasure™ includes a dosing syringe, which a parent or caregiver inserts into a protective cover, or “flow restrictor,” at the top of the bottle to measure the proper dose. In some cases, the flow restrictor was pushed into the bottle when inserting the dosing syringe.  No adverse events associated with this issue have been reported to date and the risk of a serious adverse medical event is remote.

We’ve let consumers know they can continue to use the product as long as the flow restrictor stays in place but to discontinue use if it pushes into the bottle.  We’re reaching out to consumers through our websites, the press, and bloggers to provide more information on how to use the SimpleMeasure™ dosing system.  And, we are of course, offering a refund if the consumer’s experience has been compromised.

This recall is a disappointment to all McNeil employees. Infants’ Tylenol represents 50 years of heritage, care and comfort to millions of moms, dads, and caregivers.  To learn more about the brand and recall, please visit www.tylenol.com.

I can assure you that we will bring this incredible brand back to retailers’ shelves and into the loving homes of families when we are assured we can create an exceptional experience for those we have the privilege of serving.

Please know we are making steady progress at McNeil. Our new journey to success through quality, innovation, science, and customer experience continues. We are progressing through the requirements of the Consent Decree and using this opportunity to establish a rock-solid foundation on which to build a lasting value proposition for many generations to come.

We need the support of all our Johnson & Johnson colleagues as we build new capabilities and introduce new systems and processes.  All of this work will result in the re-emergence of a world class OTC company.

Thank you,

Denice Torres
President, McNeil Consumer Healthcare


2 Responses to “Our Statement on Infants’ TYLENOL® Recall”

  1. Bob Daley says

    It is about time W.H.mangement DO something with Mc Neil . This and previous bad mangement decisions are an embrassment to us retirees ..

  2. Bruce Wheeler says

    How many times will you make major consumer mistakes without restructuring McNeill??? I worked for JJP for 18 years until my retirement (1993) and when we designed/built or purchased mfg. equipment, we established specs for the machinery and the product as well as packaging and then tested it before it went into production. It seems no one is watching Q.C. over the past 15 years. Was the dosing method tested? You guys continue to drop the ball and the stock continues to stagnate. Shame on you !!! Bruce Wheeler
    PS : I wish you would call me back and I would teach you how to manage a project. It takes dedication.

Leave a Reply

All comments will be reviewed before posting. Since this blog is about Johnson & Johnson, comments that don’t directly relate to the Company or to topics covered on this blog won’t be posted. Please see our comments policy for details.